118 related articles for article (PubMed ID: 15782557)
1. Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.
Salaj P; Marinov I; Marková M; Pohlreich D; Cetkovský P; Hrachovinová I
Prague Med Rep; 2004; 105(3):311-7. PubMed ID: 15782557
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
[TBL] [Abstract][Full Text] [Related]
3. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
4. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B
Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728
[TBL] [Abstract][Full Text] [Related]
5. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography.
Sørensen B; Ingerslev J
Haemophilia; 2005 Nov; 11 Suppl 1():1-6. PubMed ID: 16219042
[TBL] [Abstract][Full Text] [Related]
6. The effects of platelet transfusions evaluated using rotational thromboelastometry.
Flisberg P; Rundgren M; Engström M
Anesth Analg; 2009 May; 108(5):1430-2. PubMed ID: 19372316
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
Lak M; Scharling B; Blemings A; Sharifian R; Maleki Z; Daraee A; Arjmand AR; Hedner U
Haemophilia; 2008 Jan; 14(1):103-10. PubMed ID: 18070065
[TBL] [Abstract][Full Text] [Related]
8. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage.
Ahonen J; Jokela R; Korttila K
Acta Anaesthesiol Scand; 2007 Aug; 51(7):929-36. PubMed ID: 17488316
[TBL] [Abstract][Full Text] [Related]
9. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
Larsen OH; Stentoft J; Radia D; Ingerslev J; Sørensen B
Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report.
Inagaki M; Mori T; Tsunematsu Y; Ambo H; Kawai Y
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):317-22. PubMed ID: 16651876
[TBL] [Abstract][Full Text] [Related]
11. Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
Goodnough LT
Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417
[TBL] [Abstract][Full Text] [Related]
12. Enhanced thrombin generation in plasma of severe thrombocytopenic patients due to rFVIIa.
Novak M; Hiden M; Rehak T; Rosenkranz A; Zebisch A; Sill H; Klaschka S; Muntean W
Hamostaseologie; 2008 Oct; 28 Suppl 1():S77-80. PubMed ID: 18958344
[TBL] [Abstract][Full Text] [Related]
13. On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation.
Gerotziafas GT; Zervas K; Arzoglou P; Karavaggeli E; Parashou S; Van Dreden P; Christakis J; Samama MM
Br J Haematol; 2002 Jun; 117(3):705-8. PubMed ID: 12028045
[TBL] [Abstract][Full Text] [Related]
14. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers.
Johansson PI; Jacobsen N; Viuff D; Olsen EH; Rojkjaer R; Andersen S; Petersen LC; Kjalke M
Br J Haematol; 2008 Nov; 143(4):559-69. PubMed ID: 18950467
[TBL] [Abstract][Full Text] [Related]
15. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.
Rizoli SB; Boffard KD; Riou B; Warren B; Iau P; Kluger Y; Rossaint R; Tillinger M;
Crit Care; 2006; 10(6):R178. PubMed ID: 17184516
[TBL] [Abstract][Full Text] [Related]
16. Free oscillation rheometry detects changes in clot properties in pregnancy and thrombocytopenia.
Tynngård N; Lindahl TL; Ramström S; Räf T; Rugarn O; Berlin G
Platelets; 2008 Aug; 19(5):373-8. PubMed ID: 18791944
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia].
Zotz RB; Scharf RE
Hamostaseologie; 2007 Sep; 27(4):251-62. PubMed ID: 17938763
[TBL] [Abstract][Full Text] [Related]
18. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Tranholm M; Rojkjaer R; Pyke C; Kristensen AT; Klitgaard B; Lollike K; Blajchman MA
Thromb Res; 2003 Feb; 109(4):217-23. PubMed ID: 12757777
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography.
Roeloffzen WW; Kluin-Nelemans HC; Mulder AB; de Wolf JT
Blood Coagul Fibrinolysis; 2010 Jul; 21(5):389-97. PubMed ID: 20410815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
